Note: Live price is not available for this stock. Showing closing price. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
GLAXO Stock Analysis
Views
Red Flags
Positive
High and improving ROE
High and improving operating margin
Strong EPS growth and above median growth of industry
Low Debt to Equity, not much change from last year
Consistently pays dividend
Company is net cash
Negative
Expensive and at a premium to industry median P/E
Analysts have been downgrading forward EPS estimates
Low revenue growth and lower than median growth of industry
Neutral
Company's earnings are of moderate quality
Moderate dividend yield
No red flags found!
No significant red flags found in the stock.
Snapshot
See detailed analysis
GLAXO Shareholding Pattern
An overview of who owns the company. Click on chart icon to view historical movement.
GLAXO Bulk, Block & Insider Trades
GLAXO Dividends, Splits & Bonus
Dividend Events
Capital Change Events
Bonus
Rights issue
Others
Bonus(1 new shares for 1 existing shares)Bonus issue of 169406034 shares. Ex-date: 11th Sep 2018 Announced on: 24th Jul 2018
Bonus(1 new shares for 1 existing shares) Ex-date: 4th Jan 1995 Announced on: 7th Dec 1994
Rights issue(1 new shares @ 65 INR for 5 existing shares)Cum price is INR 202.5 Ex-date: 24th May 1993 Announced on: 1st Apr 1993
MergerEquity sharse alloted to the erstwhile shareholders of Burroughs Wellcome (India) Ltd. pursuant to the Scheme of Amalgamation of the company. Ex-date: 29th Oct 2004 Announced on: 10th Dec 2004
MergerEquity shares issued to shareholders of erstwhile Smithkline Beecham Pharmaceuticals (India) Ltd. as per the scheme of merger. Ex-date: 30th Nov 2001 Announced on: 1st Jan 2001
Non-renounceable scrip issue in different stockAmalgamation with <SMTP.BO>. 1 equity share of <GLAX.BO> will be allotted for every 2 equity shares of <SMTP.BO> held. Shareholder meeting on 12.4.2001 to consider the scheme Ex-date: 22nd Oct 2001 Announced on: 24th Feb 2001
Company Profile
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has... Read More
Key personnel
Ms. Renu Sud KarnadD
Non-Executive Chairman of the Board
Mr. Juby ChandyD
Chief Financial Officer, Whole-Time Director
Mr. Carson Dalton
Executive Vice President - Communications and Government Affairs
Mr. Rishikesh Jaiwant
Executive Vice President - Supply Chain Operations
Dr. Shalini Menon
Executive Vice President - Medical Affairs
Mr. Amit Pandey
Executive Vice President - Legal
Mr. Vibhuti Gupta
Vice President - Commercial Operations and Strategy
Ms. Sharmishta Mitra
Vice President - Paediatric Vaccines
View all
Incorporated on
Last Annual
Last Interim
No. of Employees
IPO date
Free Float
Website
Phone no.
Address
Frequently asked questions
What is the current share price of Glaxosmithkline Pharmaceuticals Ltd.?
The current share price of Glaxosmithkline Pharmaceuticals Ltd. is ₹ 2,393.88 as of 14 Jan 2026.
What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd.?
The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd. is 42.45 as of the latest financial data.
What is the ROE and ROCE of Glaxosmithkline Pharmaceuticals Ltd.?
Glaxosmithkline Pharmaceuticals Ltd. has a Return on Equity (ROE) of 56.52% and a Return on Capital Employed (ROCE) of 66.78% as per the latest financial reports.
What is the market cap of Glaxosmithkline Pharmaceuticals Ltd.?
The market capitalization of Glaxosmithkline Pharmaceuticals Ltd. stands at ₹ 40,553.80 Cr.
What is the dividend yield of Glaxosmithkline Pharmaceuticals Ltd.?
The dividend yield of Glaxosmithkline Pharmaceuticals Ltd. is 1.75% based on the current market price.
What is the RSI of Glaxosmithkline Pharmaceuticals Ltd.?
The Relative Strength Index (RSI) of Glaxosmithkline Pharmaceuticals Ltd. is 39.92.
What is the FII and DII holding in Glaxosmithkline Pharmaceuticals Ltd.?
Foreign Institutional Investors (FII) hold 4.63% and Domestic Institutional Investors (DII) hold 7.44% of Glaxosmithkline Pharmaceuticals Ltd. shares.
What sector does Glaxosmithkline Pharmaceuticals Ltd. belong to?
Glaxosmithkline Pharmaceuticals Ltd. operates in the Healthcare sector.
What is the beta of Glaxosmithkline Pharmaceuticals Ltd. stock?
The beta of Glaxosmithkline Pharmaceuticals Ltd. stock is 0.85, indicating its volatility relative to the broader market.
